Emmaus Q3 10-Q: Going Concern Reaffirmed, Cash Down to $971K, $1.1M New Secured Debt
EMMA has more than doubled off its 52-week low of $0.008 on light trading volume (0.1× avg).
Summary
Emmaus reported a $6.7 million nine-month net loss, $971,000 of cash, a $68.2 million working capital deficit, and renewed going-concern doubt, while adding $1.1 million of new secured debt in September 2026.
Key Events · Earnings and Guidance · EMMA
-
Going Concern Doubt Reaffirmed
Management states substantial doubt about the ability to continue as a going concern for 12 months from issuance, citing a $68.2 million working capital deficit and insufficient cash to fund obligations.
-
Cash Falls to $971,000
Cash and cash equivalents dropped to $971,000 at September 30, 2026 from $2,127,000 at December 31, 2025, against $72.9 million of current liabilities.
-
$6.7M Nine-Month Net Loss
Net loss was $6.7 million for the nine months ended September 30, 2026, versus $5.5 million a year earlier, driven by $5.6 million of interest expense and a $3.2 million conversion-feature remeasurement charge.
-
$1.1M New Secured Borrowings
September 2026 brought a $400,000 Celtic Bank/OnDeck loan (net $384,000 after a $16,000 origination fee) and a $720,000 Agile Lending term loan with a $120,000 administrative agent fee and $864,000 total repayment, both secured by company assets.
Analysis · EMMA · Life Sciences
Emmaus ended September with $971,000 of cash against $72.9 million of current liabilities and a $68.2 million working capital deficit, and management again states substantial doubt about the company's ability to continue as a going concern for 12 months. The nine-month net loss was $6.7 million. To keep operating, the company took on two new high-cost secured loans in September 2026 — $400,000 from Celtic Bank (OnDeck) and $720,000 from Agile Lending, the latter carrying a $120,000 administrative agent fee and a $864,000 total repayment obligation — both secured by substantially all assets. The NIT license that took effect May 15, 2026 shifted U.S. revenue to royalties and supply, but Q3 revenue still fell 44% to $1.9 million. With no committed financing in place, the equity is levered to any refinancing, licensing, or capital raise.
How filings like this one have moved
In the 30 days to Nov 17, 2026, 48.3% of the 2133 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.28%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, EMMA was trading at $0.02 on OTC in the Life Sciences sector, with a market capitalization of approximately $1.6M. The 52-week trading range was $0.01 to $0.09. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.